COVID-19 Impact on Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size, Status and Forecast 2020-2026

September 2020 | 92 pages | ID: C92F3A302128EN
QYResearch

Abstracts

This report focuses on the global Devic’s Syndrome (Neuromyelitis Optica) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Devic’s Syndrome (Neuromyelitis Optica) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Alexion Pharmaceuticals, Inc.
• Teva Pharmaceuticals
• Fresenius Kabi AG
• Pharmacia & Upjohn (a subsidary of Pfizer)
• Lupin Ltd.
• Sagent Pharmaceuticals, Inc.
• Zydus Pharmaceuticals, Inc.
• Sandoz Inc. (Novartis)
• Alkem Laboratories Ltd.
• Mylan Pharmaceuticals, Inc.
• Hoffmann-La Roche/ Chugai Pharmaceutical
• MedImmune LLC
• RemeGen, Ltd.

Market segment by Type, the product can be split into

• Eculizumab
• Methylprednisolone
• Azathioprine
• Mycophenolate Mofetil
• Rituximab

Market segment by Application, split into

• Hospitals
• Clinic
• Others

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Devic’s Syndrome (Neuromyelitis Optica) Treatment status, future forecast, growth opportunity, key market and key players.
• To present the Devic’s Syndrome (Neuromyelitis Optica) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Devic’s Syndrome (Neuromyelitis Optica) Treatment are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue
1.4 Market Analysis by Type
  1.4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Eculizumab
  1.4.3 Methylprednisolone
  1.4.4 Azathioprine
  1.4.5 Mycophenolate Mofetil
  1.4.6 Rituximab
1.5 Market by Application
  1.5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2020 VS 2026
  1.5.2 Hospitals
  1.5.3 Clinic
  1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Devic’s Syndrome (Neuromyelitis Optica) Treatment Industry Impact
  1.6.1 How the Covid-19 is Affecting the Devic’s Syndrome (Neuromyelitis Optica) Treatment Industry
    1.6.1.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Devic’s Syndrome (Neuromyelitis Optica) Treatment Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Devic’s Syndrome (Neuromyelitis Optica) Treatment Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Perspective (2015-2026)
2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Trends by Regions
  2.2.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Share by Regions (2015-2020)
  2.2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Strategy
  2.3.6 Primary Interviews with Key Devic’s Syndrome (Neuromyelitis Optica) Treatment Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Market Size
  3.1.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue (2015-2020)
  3.1.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Players (2015-2020)
  3.1.3 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio
  3.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2019
3.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players Head office and Area Served
3.4 Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
3.5 Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2021-2026)

5 DEVIC’S SYNDROME (NEUROMYELITIS OPTICA) TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)
5.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
6.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in North America (2019-2020)
6.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
6.4 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
7.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in Europe (2019-2020)
7.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
7.4 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

8 CHINA

8.1 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
8.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in China (2019-2020)
8.3 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
8.4 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
9.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in Japan (2019-2020)
9.3 Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
9.4 Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
10.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

11 INDIA

11.1 India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
11.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in India (2019-2020)
11.3 India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
11.4 India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2015-2020)
12.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Alexion Pharmaceuticals, Inc.
  13.1.1 Alexion Pharmaceuticals, Inc. Company Details
  13.1.2 Alexion Pharmaceuticals, Inc. Business Overview and Its Total Revenue
  13.1.3 Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
  13.1.4 Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020))
  13.1.5 Alexion Pharmaceuticals, Inc. Recent Development
13.2 Teva Pharmaceuticals
  13.2.1 Teva Pharmaceuticals Company Details
  13.2.2 Teva Pharmaceuticals Business Overview and Its Total Revenue
  13.2.3 Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
  13.2.4 Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
  13.2.5 Teva Pharmaceuticals Recent Development
13.3 Fresenius Kabi AG
  13.3.1 Fresenius Kabi AG Company Details
  13.3.2 Fresenius Kabi AG Business Overview and Its Total Revenue
  13.3.3 Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
  13.3.4 Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
  13.3.5 Fresenius Kabi AG Recent Development
13.4 Pharmacia & Upjohn (a subsidary of Pfizer)
  13.4.1 Pharmacia & Upjohn (a subsidary of Pfizer) Company Details
  13.4.2 Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview and Its Total Revenue
  13.4.3 Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
  13.4.4 Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
  13.4.5 Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development
13.5 Lupin Ltd.
  13.5.1 Lupin Ltd. Company Details
  13.5.2 Lupin Ltd. Business Overview and Its Total Revenue
  13.5.3 Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
  13.5.4 Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
  13.5.5 Lupin Ltd. Recent Development
13.6 Sagent Pharmaceuticals, Inc.
  13.6.1 Sagent Pharmaceuticals, Inc. Company Details
  13.6.2 Sagent Pharmaceuticals, Inc. Business Overview and Its Total Revenue
  13.6.3 Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
  13.6.4 Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
  13.6.5 Sagent Pharmaceuticals, Inc. Recent Development
13.7 Zydus Pharmaceuticals, Inc.
  13.7.1 Zydus Pharmaceuticals, Inc. Company Details
  13.7.2 Zydus Pharmaceuticals, Inc. Business Overview and Its Total Revenue
  13.7.3 Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
  13.7.4 Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
  13.7.5 Zydus Pharmaceuticals, Inc. Recent Development
13.8 Sandoz Inc. (Novartis)
  13.8.1 Sandoz Inc. (Novartis) Company Details
  13.8.2 Sandoz Inc. (Novartis) Business Overview and Its Total Revenue
  13.8.3 Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
  13.8.4 Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
  13.8.5 Sandoz Inc. (Novartis) Recent Development
13.9 Alkem Laboratories Ltd.
  13.9.1 Alkem Laboratories Ltd. Company Details
  13.9.2 Alkem Laboratories Ltd. Business Overview and Its Total Revenue
  13.9.3 Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
  13.9.4 Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
  13.9.5 Alkem Laboratories Ltd. Recent Development
13.10 Mylan Pharmaceuticals, Inc.
  13.10.1 Mylan Pharmaceuticals, Inc. Company Details
  13.10.2 Mylan Pharmaceuticals, Inc. Business Overview and Its Total Revenue
  13.10.3 Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
  13.10.4 Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
  13.10.5 Mylan Pharmaceuticals, Inc. Recent Development
13.11 Hoffmann-La Roche/ Chugai Pharmaceutical
  10.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
  10.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview and Its Total Revenue
  10.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
  10.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
  10.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development
13.12 MedImmune LLC
  10.12.1 MedImmune LLC Company Details
  10.12.2 MedImmune LLC Business Overview and Its Total Revenue
  10.12.3 MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
  10.12.4 MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
  10.12.5 MedImmune LLC Recent Development
13.13 RemeGen, Ltd.
  10.13.1 RemeGen, Ltd. Company Details
  10.13.2 RemeGen, Ltd. Business Overview and Its Total Revenue
  10.13.3 RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
  10.13.4 RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
  10.13.5 RemeGen, Ltd. Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue
Table 3. Ranking of Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Eculizumab
Table 6. Key Players of Methylprednisolone
Table 7. Key Players of Azathioprine
Table 8. Key Players of Mycophenolate Mofetil
Table 9. Key Players of Rituximab
Table 10. COVID-19 Impact Global Market: (Four Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Forecast Scenarios)
Table 11. Opportunities and Trends for Devic’s Syndrome (Neuromyelitis Optica) Treatment Players in the COVID-19 Landscape
Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 13. Key Regions/Countries Measures against Covid-19 Impact
Table 14. Proposal for Devic’s Syndrome (Neuromyelitis Optica) Treatment Players to Combat Covid-19 Impact
Table 15. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions (2015-2020)
Table 19. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Strategy
Table 25. Main Points Interviewed from Key Devic’s Syndrome (Neuromyelitis Optica) Treatment Players
Table 26. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Players (2015-2020) (Million US$)
Table 27. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Players (2015-2020)
Table 28. Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment as of 2019)
Table 29. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
Table 32. Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US$)
Table 35. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Share by Type (2015-2020)
Table 36. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2021-2026)
Table 37. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Share by Application (2015-2020)
Table 38. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US$)
Table 39. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Share by Application (2021-2026)
Table 40. North America Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)
Table 42. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US$)
Table 43. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)
Table 44. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US$)
Table 45. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)
Table 46. Europe Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)
Table 48. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)
Table 50. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)
Table 52. China Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US$)
Table 53. China Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)
Table 54. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US$)
Table 55. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)
Table 56. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US$)
Table 57. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)
Table 58. Japan Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)
Table 60. Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)
Table 62. Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)
Table 66. Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)
Table 68. Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)
Table 70. India Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US$)
Table 71. India Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)
Table 72. India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US$)
Table 73. India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)
Table 74. India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US$)
Table 75. India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share (2019-2020)
Table 78. Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2015-2020)
Table 80. Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2015-2020)
Table 82. Alexion Pharmaceuticals, Inc. Company Details
Table 83. Alexion Pharmaceuticals, Inc. Business Overview
Table 84. Alexion Pharmaceuticals, Inc. Product
Table 85. Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US$)
Table 86. Alexion Pharmaceuticals, Inc. Recent Development
Table 87. Teva Pharmaceuticals Company Details
Table 88. Teva Pharmaceuticals Business Overview
Table 89. Teva Pharmaceuticals Product
Table 90. Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US$)
Table 91. Teva Pharmaceuticals Recent Development
Table 92. Fresenius Kabi AG Company Details
Table 93. Fresenius Kabi AG Business Overview
Table 94. Fresenius Kabi AG Product
Table 95. Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US$)
Table 96. Fresenius Kabi AG Recent Development
Table 97. Pharmacia & Upjohn (a subsidary of Pfizer) Company Details
Table 98. Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview
Table 99. Pharmacia & Upjohn (a subsidary of Pfizer) Product
Table 100. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US$)
Table 101. Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development
Table 102. Lupin Ltd. Company Details
Table 103. Lupin Ltd. Business Overview
Table 104. Lupin Ltd. Product
Table 105. Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US$)
Table 106. Lupin Ltd. Recent Development
Table 107. Sagent Pharmaceuticals, Inc. Company Details
Table 108. Sagent Pharmaceuticals, Inc. Business Overview
Table 109. Sagent Pharmaceuticals, Inc. Product
Table 110. Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US$)
Table 111. Sagent Pharmaceuticals, Inc. Recent Development
Table 112. Zydus Pharmaceuticals, Inc. Company Details
Table 113. Zydus Pharmaceuticals, Inc. Business Overview
Table 114. Zydus Pharmaceuticals, Inc. Product
Table 115. Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US$)
Table 116. Zydus Pharmaceuticals, Inc. Recent Development
Table 117. Sandoz Inc. (Novartis) Business Overview
Table 118. Sandoz Inc. (Novartis) Product
Table 119. Sandoz Inc. (Novartis) Company Details
Table 120. Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US$)
Table 121. Sandoz Inc. (Novartis) Recent Development
Table 122. Alkem Laboratories Ltd. Company Details
Table 123. Alkem Laboratories Ltd. Business Overview
Table 124. Alkem Laboratories Ltd. Product
Table 125. Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US$)
Table 126. Alkem Laboratories Ltd. Recent Development
Table 127. Mylan Pharmaceuticals, Inc. Company Details
Table 128. Mylan Pharmaceuticals, Inc. Business Overview
Table 129. Mylan Pharmaceuticals, Inc. Product
Table 130. Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US$)
Table 131. Mylan Pharmaceuticals, Inc. Recent Development
Table 132. Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
Table 133. Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
Table 134. Hoffmann-La Roche/ Chugai Pharmaceutical Product
Table 135. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US$)
Table 136. Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development
Table 137. MedImmune LLC Company Details
Table 138. MedImmune LLC Business Overview
Table 139. MedImmune LLC Product
Table 140. MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US$)
Table 141. MedImmune LLC Recent Development
Table 142. RemeGen, Ltd. Company Details
Table 143. RemeGen, Ltd. Business Overview
Table 144. RemeGen, Ltd. Product
Table 145. RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020) (Million US$)
Table 146. RemeGen, Ltd. Recent Development
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type: 2020 VS 2026
Figure 2. Eculizumab Features
Figure 3. Methylprednisolone Features
Figure 4. Azathioprine Features
Figure 5. Mycophenolate Mofetil Features
Figure 6. Rituximab Features
Figure 7. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2020 VS 2026
Figure 8. Hospitals Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Devic’s Syndrome (Neuromyelitis Optica) Treatment Report Years Considered
Figure 12. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions: 2020 VS 2026
Figure 14. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Players in 2019
Figure 17. Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2019
Figure 19. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Alexion Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Alexion Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
Figure 28. Teva Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Teva Pharmaceuticals Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
Figure 30. Fresenius Kabi AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Fresenius Kabi AG Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
Figure 32. Pharmacia & Upjohn (a subsidary of Pfizer) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
Figure 34. Lupin Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Lupin Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
Figure 36. Sagent Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Sagent Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
Figure 38. Zydus Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Zydus Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
Figure 40. Sandoz Inc. (Novartis) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Sandoz Inc. (Novartis) Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
Figure 42. Alkem Laboratories Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Alkem Laboratories Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
Figure 44. Mylan Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Mylan Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
Figure 46. Hoffmann-La Roche/ Chugai Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
Figure 48. MedImmune LLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. MedImmune LLC Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
Figure 50. RemeGen, Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. RemeGen, Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2015-2020)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed